Prognostic value of [18F]FDG PET/CT and PERCIST criteria in patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan.
Saved in:
| Title: | Prognostic value of [18F]FDG PET/CT and PERCIST criteria in patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan. |
|---|---|
| Authors: | Frega J; Université de Strasbourg Faculté de Médecine, 4 Rue Kirschleger, Strasbourg, 67000, France. frega.juliette@gmail.com.; Nuclear Medicine and Molecular Imaging, Institut public de cancérologie Strauss Europe, Strasbourg, France. frega.juliette@gmail.com., Somme L; Oncology, Institut public de cancérologie Strauss Europe, Strasbourg, France., Martin T; Pharmacy, Institut public de cancérologie Strauss Europe, Strasbourg, France., Petit T; Oncology, Institut public de cancérologie Strauss Europe, Strasbourg, France., Salvadori J; Radiophysics, Institut public de cancérologie Strauss Europe, Strasbourg, France., Bund C; Nuclear Medicine and Molecular Imaging, Institut public de cancérologie Strauss Europe, Strasbourg, France., Somme F; Nuclear Medicine and Molecular Imaging, Institut public de cancérologie Strauss Europe, Strasbourg, France. |
| Source: | European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2026 Jul 01. Date of Electronic Publication: 2026 Jul 01. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1619-7089 (Electronic) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1619-7089 |
|---|---|
| DOI: | 10.1007/s00259-026-08029-4 |
